THE LAW RELATING TO CLINICAL TRIALS IN INDIA: THE PREVAILING DEFICIENCIES AND THE ROAD AHEAD
Bibliographic record
Abstract
Clinical trials stand at the crux of medical advancement, serving as the vital link between laboratory research and the availability of new treatments for patients’ ailments. In a world increasingly reliant on evidence-based medicine, the importance of rigorous, ethical, and well-regulated clinical trials cannot be overstated. However, the dynamic and multifaceted nature of clinical trials raises complex legal, ethical, and social issues, particularly in a diverse and populous nation like India. This book, “The Law Relating to Clinical Trials in India: The Prevailing Deficiencies and the Road Ahead,” by Ms. Gayathri N. M. and Ms. Nidhi R, provides a comprehensive analysis of India’s legal framework governing clinical trials. It assesses the current state of the law, identifies the deficiencies therein, and offers a thought-provoking exploration of the path to rectifying these shortcomings. The pages within unfold the historical tapestry of clinical trials, setting the stage with an exploration of their evolution both globally and within the Indian context. The book ventures into the intricate lattice of regulations and guidelines that govern clinical trials in India and juxtaposes them against the global standards set by more developed frameworks in the United States and Canada. Through the chapters, the reader is invited to examine the role of Indian courts in interpreting and applying the laws concerning clinical trials, often acting as bulwarks against unethical practices. The narrative further delves into the comparisons between regulatory systems, thereby drawing lessons from international best practices. Perhaps most critically, this work does not shy away from discussing the challenges and deficiencies that mar the current Indian clinical trial landscape. It ventures into the depths of the 2019 New Drugs and Clinical Trials Rules (NDCTR), unearthing its flaws and potential. The Covid-19 pandemic and the resultant vaccine fast approvals present a case study, highlighting the urgency for reform in the face of unprecedented global health challenges. As we reach the denouement in the concluding chapter, the authors synthesize their findings and articulate a series of well-reasoned suggestions. Their vision for the future of India’s clinical trial legal system is one of pragmatism and hope, guided by the twin stars of participant safety and scientific integrity. The preface serves as an invitation to readers — scholars, practitioners, policymakers, and anyone with an interest in the crossroads of law, medicine, and ethics — to embark on this intellectual journey. The goal is not only to inform but also to inspire action that will shape a more robust, just, and effective framework for clinical trials in India. In closing, this book aims to contribute meaningfully to the discourse on improving the regulatory environment for clinical trials in India, ensuring that the nation’s laws keep pace with scientific progress while safeguarding the rights and welfare of participants.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.047 | 0.084 |
| Meta-epidemiology (narrow) | 0.001 | 0.001 |
| Meta-epidemiology (broad) | 0.001 | 0.001 |
| Bibliometrics | 0.003 | 0.008 |
| Science and technology studies | 0.014 | 0.050 |
| Scholarly communication | 0.044 | 0.017 |
| Open science | 0.004 | 0.009 |
| Research integrity | 0.012 | 0.038 |
| Insufficient payload (model declined to judge) | 0.002 | 0.001 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".